empagliflozin glp 1 APhA 2025: GLP-1 Receptor Agonists vs SGLT2 Inhibitors Show Varied Benefit for Cardiovascular Outcomes in Patients With Diabetes

Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology

24.45

★★★★☆4.8 (126)

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study | Diabetologia

22.31

★★★★★4.9 (98)

New diabetes medicines funded: empagliflozin and dulaglutide

20.30

★★★★★5.0 (157)

Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study

28.52

★★★★★4.7 (84)

3. Integration of GLP-1RA or SGLT2i in Patients With T2D With or at Risk of atherosclerotic CVD

20.76

★★★★★4.9 (203)

Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique | Diabetes Therapy

23.62

★★★★★5.0 (176)

Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records

22.58

★★★★★4.8 (132)